ADGC Publications

Found 25 results
Filters: Keyword is tau Proteins  [Clear All Filters]
2022
Jun GR, You Y, Zhu C, Meng G, Chung J, Panitch R, Hu J, Xia W, Bennett DA, Foroud TM et al..  2022.  Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer's disease.. Alzheimers Dement. 18(11):2042-2054.
2018
Deming Y, Dumitrescu L, Barnes LL, Thambisetty M, Kunkle B, Gifford KA, Bush WS, Chibnik LB, Mukherjee S, De Jager PL et al..  2018.  Sex-specific genetic predictors of Alzheimer's disease biomarkers.. Acta Neuropathol. 136(6):857-872.
Ikezu T, Chen CD, DeLeo AM, Zeldich E, M Fallin D, Kanaan NM, Lunetta KL, Abraham CR, Logue MW, Farrer LA.  2018.  Tau Phosphorylation is Impacted by Rare AKAP9 Mutations Associated with Alzheimer Disease in African Americans.. J Neuroimmune Pharmacol. 13(2):254-264.
2017
Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan I.  2017.  Genetic influences on cognition in progressive supranuclear palsy.. Mov Disord. 32(12):1764-1771.
Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MVictoria, Budde J et al..  2017.  Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.. Acta Neuropathol. 133(5):839-856.
Yokoyama JS, Karch CM, Fan CC, Bonham LW, Kouri N, Ross OA, Rademakers R, Kim J, Wang Y, Höglinger GU et al..  2017.  Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia.. Acta Neuropathol. 133(5):825-837.
2016
Allen M, Burgess JD, Ballard T, Serie D, Wang X, Younkin CS, Sun Z, Kouri N, Baheti S, Wang C et al..  2016.  Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci.. Acta Neuropathol. 132(2):197-211.
Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert J-C, Chung J, Naj AC, Kunkle BW, Wang L-S, Bis JC, Bellenguez C et al..  2016.  A novel Alzheimer disease locus located near the gene encoding tau protein.. Mol Psychiatry. 21(1):108-17.
2015
Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, Holland D, Brewer JB, Chen C-H, Thompson WK et al..  2015.  Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus.. Mol Psychiatry. 20(12):1588-95.
Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, Baker M, Finch NCole A, Yoon H, Kim J et al..  2015.  Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.. Nat Commun. 6:7247.
Wheeler JM, McMillan PJ, Hawk M, Iba M, Robinson L, Xu GJ, Dombroski BA, Jeong D, Dichter MA, Juul H et al..  2015.  High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.. Acta Neuropathol Commun. 3:33.
2014
McMillan CT, Toledo JB, Avants BB, Cook PA, Wood EM, Suh ER, Irwin DJ, Powers J, Olm C, Elman L et al..  2014.  Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration.. Neurobiol Aging. 35(6):1473-82.
Kauwe JSK, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, Staley LA, Karch CM, Harari O, Cruchaga C et al..  2014.  Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation.. PLoS Genet. 10(10):e1004758.
Carney RM, Kohli MA, Kunkle BW, Naj AC, Gilbert JR, Züchner S, Pericak-Vance MA.  2014.  Parkinsonism and distinct dementia patterns in a family with the MAPT R406W mutation.. Alzheimers Dement. 10(3):360-5.
Toledo JB, Van Deerlin VM, Lee EB, Suh ER, Baek Y, Robinson JL, Xie SX, McBride J, Wood EM, Schuck T et al..  2014.  A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.. Alzheimers Dement. 10(4):477-484.e1.
Jun G, Asai H, Zeldich E, Drapeau E, Chen CD, Chung J, Park J-H, Kim S, Haroutunian V, Foroud T et al..  2014.  PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation.. Ann Neurol. 76(3):379-92.
Ramirez A, van der Flier WM, Herold C, Ramonet D, Heilmann S, Lewczuk P, Popp J, Lacour A, Drichel D, Louwersheimer E et al..  2014.  SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.. Hum Mol Genet. 23(24):6644-58.
Warmus BA, Sekar DR, McCutchen E, Schellenberg GD, Roberts RC, McMahon LL, Roberson ED.  2014.  Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia.. J Neurosci. 34(49):16482-95.
2013
Cruchaga C, Kauwe JSK, Harari O, Jin SChih, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D et al..  2013.  GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.. Neuron. 78(2):256-68.
Stutzbach LD, Xie SX, Naj AC, Albin R, Gilman S, M Y Lee V, Trojanowski JQ, Devlin B, Schellenberg GD.  2013.  The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease.. Acta Neuropathol Commun. 1:31.
2012
Coppola G, Chinnathambi S, Lee JJiYong, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R et al..  2012.  Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases.. Hum Mol Genet. 21(15):3500-12.
2011
Jayadev S, Nochlin D, Poorkaj P, Steinbart EJ, Mastrianni JA, Montine TJ, Ghetti B, Schellenberg GD, Bird TD, Leverenz JB.  2011.  Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype.. Ann Neurol. 69(4):712-20.
Höglinger GU, Melhem NM, Dickson DW, Sleiman PMA, San Wang L-, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE et al..  2011.  Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.. Nat Genet. 43(7):699-705.
2010
Han M-R, Schellenberg GD, San Wang L-.  2010.  Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.. BMC Neurol. 10:90.
Melrose HL, Dächsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, Kent CB, Korvatska E, Taylor JP, Witten L et al..  2010.  Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.. Neurobiol Dis. 40(3):503-17.